Big Ideas 2026: Multiomics
As multiomics moves beyond bulk genomics into single‑cell, spatial, and multimodal approaches, demand for instruments, consumables, and automation should rise. This play focuses on the infrastructure and toolmakers—‘picks and shovels’—that enable greater data generation and analysis across research and clinical workflows.
Linked assets
Featured tickers: TXG (10x Genomics) — single‑cell and spatial genomics tools; TMO (Thermo Fisher Scientific) — broad life‑science tools, consumables, and lab automation; PACB (Pacific Biosciences) — long‑read sequencing with upside if long reads gain share; ILMN (Illumina) — incumbent sequencing provider that could benefit from higher clinical volumes but faces disruption risk.
TXG is 10x Genomics, Inc., a Healthcare equity in Health Information Services, developing tools and consumables for single-cell and spatial genomics research.
Direct exposure to single-cell/spatial multiomics workflows as labs expand beyond bulk genomics.
TMO is Thermo Fisher Scientific Inc, a Healthcare equity in the Diagnostics & Research industry.
Broadest diversified exposure across life-science tools/consumables and lab automation supporting multiomics scale-up.
PACB is an equity of Pacific Biosciences of Californ, a Healthcare sector company in the Medical Devices industry.
Potential share gains if richer long-read data becomes a larger component of multiomic pipelines; higher execution risk.
Illumina, Inc.
Could benefit from higher clinical volumes, but faces disruption/price pressure if long-read/alternative technologies gain share.
Source proof
Source proof: Strong source proof | 4 directional assets | 1 supporting author | headline-like title review
Related source materials include ARK’s Big Ideas 2026 segments on multiomics-adjacent themes (AI Productivity, Bitcoin) and a mix of podcast/video entries. Several items were non-substantive or outside finance; relevant research notes were used to inform the play thesis where available.
Discussion touches on Apple WWDC/Siri AI positioning (long-term AI strategy), AI model/cloud partnerships that may be short-term (Anthropic/Google), and large-scale data center buildouts (xAI/SpaceX mentioned but private). Actionable public-market read-through is mainly: AAPL (on-device AI/WWDC), major cloud platforms (GOOGL, MSFT, AMZN), and AI data-center supply chain (NVDA).
ARK Big Ideas 2026 segment on tokenized assets references U.S. regulatory momentum ("GENIUS Act" in June 2025) and cites JPMorgan announcements around tokenized stocks on its platform. Content is high-level and lacks concrete details (no specific products, timelines, volumes, or economics), limiting near-term trade actionability.
Video-style commentary featuring Cathie Wood riding in a Tesla Robotaxi in Austin and arguing the Robotaxi rollout is shifting from slow progress to rapid adoption (“slowly…then all at once”), emphasizing safety vs human driving and long-term (10-year) disruption. The content is thematic and promotional; it provides limited hard catalysts/dates but supports a medium/long-horizon autonomy thesis centered on Tesla.
Transcript-style macro discussion (Cathie Wood context) touching on: strong jobs report vs weak market, USD (DXY) dynamics, foreign selling of US Treasuries, gold selling by some countries, M2 leading indicators pointing to disinflation/deflation, long-bond yield implications, OPEC “splintering”/UAE production, PPI/core PPI cooling, decelerating corporate revenue growth (margin implications), and housing buyer/seller imbalance. Content is thematic but low on concrete timing/levels.
The source is a fragmented discussion about large private-company revenue/ARR milestones (e.g., “$30B ARR”), comparisons to early NASDAQ-era growth, and a broad “historic IPO wave” framing, with mentions of SpaceX, xAI/Grok, Anthropic, and OpenAI. It contains no concrete timing, pricing, filing details, or specific IPO candidates beyond speculative references, so actionable trading signal is limited.
Podcast-style discussion with Bryan Johnson framed around “don’t die”/longevity: prioritizing interventions that extend healthspan, skepticism toward many supplements (NMN/NR, B12 shots), importance of sleep architecture, and a view that AGI/ASI could become a major driver of longevity progress. No company-specific catalysts, products, trials, or investable signals are provided; ARK disclaimers included.
Podcast discussion: Blue Origin rocket explosion and implications for space-launch competition (SpaceX vs. Blue Origin) plus debate on AI infrastructure/GPU demand, pricing, supply constraints, and bubble/off-balance-sheet concerns. Mentions are thematic; no specific public-company tickers are explicitly cited. Actionable angle comes from mapping themes to liquid, tradable public proxies in aerospace/launch and AI infrastructure semis.
ARK Invest discussion frames SpaceX/Starlink as a large, long-duration space/AI connectivity platform opportunity (orbital data centers, AI satellites by ~2028), emphasizes SpaceX cost/scale advantages (Wright’s Law, vertical integration), and notes industry risks/competition (e.g., Blue Origin mishap) and SpaceX-specific risk factors. Direct tradability is limited because SpaceX is private; the actionable angle is via public proxies in launch/satellite comms, aerospace incumbents, and compute/semis tied to space-based networking/compute narratives.
Supporting authors
This play was prepared by ARK research analysts synthesizing public episodes, presentations, and internal Big Ideas 2026 materials. Author count: 1.
Unlock full thesis monitoring
For a deeper read, download or view the full Big Ideas 2026 report and model to assess how multiomics infrastructure exposure fits within diversified portfolio strategies.